Development of a First-Generation Stereocontrolled Manufacturing Process of TRPA1 Inhibitor GDC-6599

IF 3.5 3区 化学 Q2 CHEMISTRY, APPLIED Organic Process Research & Development Pub Date : 2024-05-23 DOI:10.1021/acs.oprd.4c00134
Allen Y. Hong*, Katarzyna A. Piechowicz, Jacob C. Timmerman, Haiming Zhang, Carmela Molinaro and Francis Gosselin, 
{"title":"Development of a First-Generation Stereocontrolled Manufacturing Process of TRPA1 Inhibitor GDC-6599","authors":"Allen Y. Hong*,&nbsp;Katarzyna A. Piechowicz,&nbsp;Jacob C. Timmerman,&nbsp;Haiming Zhang,&nbsp;Carmela Molinaro and Francis Gosselin,&nbsp;","doi":"10.1021/acs.oprd.4c00134","DOIUrl":null,"url":null,"abstract":"<p >We report a fit-for-purpose, stereocontrolled, and chromatography-free first-generation manufacturing process for GDC-6599 (<b>1</b>), a TRPA1 inhibitor, to enable first-in-human clinical trials. Key steps in the process include consecutive KRED-mediated asymmetric ketone reductions, nucleophilic cyanation, 1,2,4-oxadiazole formation, and late stage purinone <i>N</i>-alkylation. The 13-step process successfully produced 4.39 kg of GDC-6599 (<b>1</b>) in 11% overall yield with 99.6 A% HPLC purity, &gt;99.9:0.1 er, and &gt;99.9:0.1 dr.</p>","PeriodicalId":55,"journal":{"name":"Organic Process Research & Development","volume":"28 6","pages":"2325–2333"},"PeriodicalIF":3.5000,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Organic Process Research & Development","FirstCategoryId":"92","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.oprd.4c00134","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, APPLIED","Score":null,"Total":0}
引用次数: 0

Abstract

We report a fit-for-purpose, stereocontrolled, and chromatography-free first-generation manufacturing process for GDC-6599 (1), a TRPA1 inhibitor, to enable first-in-human clinical trials. Key steps in the process include consecutive KRED-mediated asymmetric ketone reductions, nucleophilic cyanation, 1,2,4-oxadiazole formation, and late stage purinone N-alkylation. The 13-step process successfully produced 4.39 kg of GDC-6599 (1) in 11% overall yield with 99.6 A% HPLC purity, >99.9:0.1 er, and >99.9:0.1 dr.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
开发 TRPA1 抑制剂 GDC-6599 的第一代立体可控制造工艺
我们报告了 TRPA1 抑制剂 GDC-6599 (1) 的适合目的、立体可控和无色谱的第一代生产工艺,以实现首次人体临床试验。该工艺的关键步骤包括连续的 KRED 介导的不对称酮还原、亲核氰化、1,2,4-噁二唑形成和后期的嘌呤酮 N-烷基化。该 13 步工艺成功制备了 4.39 千克 GDC-6599 (1),总收率为 11%,HPLC 纯度为 99.6A%,ER 值为 99.9:0.1,DR 值为 99.9:0.1。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.90
自引率
14.70%
发文量
251
审稿时长
2 months
期刊介绍: The journal Organic Process Research & Development serves as a communication tool between industrial chemists and chemists working in universities and research institutes. As such, it reports original work from the broad field of industrial process chemistry but also presents academic results that are relevant, or potentially relevant, to industrial applications. Process chemistry is the science that enables the safe, environmentally benign and ultimately economical manufacturing of organic compounds that are required in larger amounts to help address the needs of society. Consequently, the Journal encompasses every aspect of organic chemistry, including all aspects of catalysis, synthetic methodology development and synthetic strategy exploration, but also includes aspects from analytical and solid-state chemistry and chemical engineering, such as work-up tools,process safety, or flow-chemistry. The goal of development and optimization of chemical reactions and processes is their transfer to a larger scale; original work describing such studies and the actual implementation on scale is highly relevant to the journal. However, studies on new developments from either industry, research institutes or academia that have not yet been demonstrated on scale, but where an industrial utility can be expected and where the study has addressed important prerequisites for a scale-up and has given confidence into the reliability and practicality of the chemistry, also serve the mission of OPR&D as a communication tool between the different contributors to the field.
期刊最新文献
Operando NMR Monitoring of Electrochemical Reactions Development of a Scalable Process for TNG348: A Potent, Selective, and Orally Bioavailable USP1 Inhibitor Particle Size Control in Perampanel and Taurine via Continuous Crystallization Using MSMPR Sonocrystallizer: Comparison to Couette–Taylor Crystallizer Kilogram-Scale Stereoselective Synthesis of an N-Methylprolinol Derivative by Enzymatic Transformation Scalable Continuous Flow Reduction for the Synthesis of Emtricitabine
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1